Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cerus Corporation    CERS

CERUS CORPORATION

(CERS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/31/2020 04/01/2020 04/02/2020 04/03/2020 04/06/2020 Date
4.65(c) 4.5(c) 4.53(c) 4.57(c) 4.86(c) Last
2 148 309 1 780 620 2 157 060 1 379 957 2 110 422 Volume
-0.43% -3.23% +0.67% +0.88% +6.35% Change
More quotes
Financials (USD)
Sales 2020 88,4 M
EBIT 2020 -63,0 M
Net income 2020 -62,6 M
Debt 2020 -
Yield 2020 -
Sales 2021 114 M
EBIT 2021 -49,7 M
Net income 2021 -46,8 M
Debt 2021 -
Yield 2021 -
P/E ratio 2020 -11,5x
P/E ratio 2021 -15,8x
Capi. / Sales2020 8,31x
Capi. / Sales2021 6,44x
Capitalization 735 M
More Financials
Company
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological... 
More about the company
Surperformance© ratings of Cerus Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CERUS CORPORATION
04/06CERUS CORPORATION : Provides Update on COVID-19 Related Activities
BU
04/02CERUS CORPORATION : Announces the Inclusion of Pathogen Reduction Technology in ..
BU
04/02CERUS : University Hospital Basel, Switzerland Transfuses First Two COVID-19 Pat..
BU
03/26CERUS : Forms Group to Research Optimal Production of COVID-19 Convalescent Plas..
BU
03/02CERUS CORP : Change in Directors or Principal Officers, Financial Statements and..
AQ
03/02CERUS CORPORATION : Announces Strategic Organizational Changes
BU
02/25CERUS CORPORATION : to Participate in Upcoming Investor Conferences
BU
02/21CERUS : Management's Discussion and Analysis of Financial Condition and Results ..
AQ
02/20CERUS : 4Q Earnings Snapshot
AQ
02/20CERUS CORP : Results of Operations and Financial Condition, Financial Statements..
AQ
02/20CERUS CORPORATION : Announces Record Fourth Quarter and Full Year 2019 Financial..
BU
02/18CERUS : U.S. Department of Defense Awards Funding for Study to Evaluate the Use ..
BU
02/12CERUS CORPORATION : to Release Fourth Quarter and Full Year 2019 Financial Resul..
BU
01/31CERUS CORPORATION : Announces Closing of Public Offering of Common Stock and Ful..
BU
01/30CERUS CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
News in other languages on CERUS CORPORATION
2014CERUS CORPORATION : publication des résultats trimestriels
2013CERUS CORPORATION : publication des résultats trimestriels
2012CERUS CORPORATION : publication des résultats trimestriels
2007CERUS CORP : Cerus annonce avoir passé un accord portant sur la fourniture du sy..
2007CERUS CORP : INTERCEPT Plasma inscrit au Journal Officiel français
More news
Chart CERUS CORPORATION
Duration : Period :
Cerus Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CERUS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 8,00  $
Last Close Price 4,53  $
Spread / Highest target 110%
Spread / Average Target 76,6%
Spread / Lowest Target 54,5%
EPS Revisions
Managers
NameTitle
William Mariner Greenman President, Chief Executive Officer & Director
Daniel N. Swisher Chairman
Vivek K. Jayaraman Chief Operating Officer
Kevin Dennis Green Chief Financial Officer & Vice President-Finance
Laurence M. Corash Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CERUS CORPORATION15.17%754
STRYKER CORPORATION-29.47%62 405
SMITH & NEPHEW PLC-25.62%15 597
WRIGHT MEDICAL GROUP N.V.-13.65%3 691
INSPIRE MEDICAL SYSTEMS, INC.-33.30%1 456
GLAUKOS CORPORATION-46.37%1 350